Platelets play a key role in the pathogenesis of ventricular assist device (VAD) thrombosis; therefore, antiplatelet drugs are essential, both in the acute phase and in the long-term follow-up in VAD management. Aspirin is the most used agent and still remains the first-choice drug for lifelong administration after VAD implantation. Anticoagulant drugs are usually recommended, but with a wide range of efficacy targets. Dual antiplatelet therapy, targeting more than one pathway of platelet activation, has been used for patients developing a thrombotic event, despite an increased risk of bleeding complications. Although different strategies have been attempted, bleeding and thrombotic events remain frequent and there are no uniform strategies adopted for pharmacological management in the short and mid- or long-term follow up. The aim of this article is to provide an overview of the evidence from randomized clinical trials and observational studies with a focus on the pathophysiologic mechanisms underlying bleeding and thrombosis in VAD patients and the best antithrombotic regimens available.
|Titolo:||Antithrombotic therapy in ventricular assist device (VAD) management : from ancient beliefs to updated evidence : a narrative review|
MORICI, NUCCIA (Corresponding)
|Parole Chiave:||Anticoagulation; Antiplatelet therapy; Antithrombotic management; Assist device; Bleeding; Thrombosis; Cardiology and Cardiovascular Medicine|
|Settore Scientifico Disciplinare:||Settore MED/01 - Statistica Medica|
|Data di pubblicazione:||30-giu-2018|
|Digital Object Identifier (DOI):||10.1016/j.ijcha.2018.06.005|
|Appare nelle tipologie:||01 - Articolo su periodico|